Industry Overview - The ophthalmic drug development sector is referred to as a "golden track," with opportunities to extend patent periods and develop new indications to maintain market dominance [1] - The global ophthalmic drug market has seen rapid growth, increasing from $32.4 billion in 2018 to $38.7 billion in 2022, and is projected to reach $57 billion by 2027 and $85.8 billion by 2032 [1] Company Profile - Cloudbreak Pharma Inc. (拨康视云) is a clinical-stage ophthalmic biotechnology company focused on developing various therapies [2][3] - The company has submitted its listing application to the Hong Kong Stock Exchange multiple times, with its latest submission on June 11 [2] - Cloudbreak Pharma has raised approximately $154 million across four funding rounds, with a post-Series C valuation of $469 million [2] Financial Performance - The company has reported cumulative losses of $295 million over three years, with annual losses of approximately $67 million, $129 million, and $99 million for 2022, 2023, and 2024, respectively [7] - The company anticipates increased losses in 2025 due to rising employee costs related to share-based payments [7] - Research and development expenses have been increasing, with figures of $15 million, $28 million, and $38 million for the respective years [9] Product Pipeline - Cloudbreak Pharma has developed a pipeline of candidate drugs, including two core products: CBT-001 for treating pterygium and CBT-009 for juvenile myopia [3][5] - CBT-001 is currently in Phase 3 multi-regional clinical trials in the U.S. and China, expected to complete by the end of 2025 [11] - The global market for pterygium treatment is projected to reach $273.4 million by 2027, with a compound annual growth rate (CAGR) of 56% [11] Commercialization Challenges - The company has licensed part of the rights for CBT-001 to a partner, which may expedite commercialization but could also reduce profitability for Cloudbreak Pharma [15] - The financial situation of the company is precarious, with increasing liabilities and negative cash flow from operations, necessitating external financing [9][10]